Science Current Events | Science News | Brightsurf.com
 

OptiNose presents data on highly effective migraine treatment

June 30, 2008
OptiNose announced today that it presented important new data demonstrating the superior performance of its novel nasal drug delivery device with sumatriptan for the treatment of migraines. The Phase II results indicate that the drug-device combination achieves migraine relief as quickly and efficiently as injections without the discomfort, inconvenience and risk of needle-stick injuries. OptiNose presented the data at the Annual Scientific Meeting of the American Headache Society in Boston.

Headache relief was achieved in 74.3% and 83.8% of patients at 60 minutes and 120 minutes after administration, respectively, and 48.6% of patients remained pain free after 48 hours. The results were statistically significant when compared to the study's placebo group. The study also confirmed earlier Phase I results. In the Phase I study, the OptiNose powder nasal drug delivery device achieved the maximum sumatriptan concentration in the blood at a median time of 20 minutes after administration. This result was comparable to injections and much faster than other intranasal delivery technologies.

"We are excited to develop this new treatment for the approximately 30 million Americans who suffer from migraines," said Per Djupesland, M.D., Ph.D., the study's co-author and Chief Scientific Officer at OptiNose AS. "Our new device combination will offer patients a much-needed alternative to existing, slower-acting nasal inhalers and tablets and painful injections."

The user feedback from patients who participated in the study was also very encouraging. "The majority of the migraine patients found the device to be both comfortable and easy to use." said Dr Djupesland. "We believe that we can offer a unique therapy for migraine sufferers, combining fast relief, low side effects and high user compliance."

Unlike traditional nasal delivery devices, the unique design of the OptiNose device ensures that drug is delivered to target sites throughout the entire nasal cavity, achieving optimal dose delivery while avoiding the risk of drug deposition to the lungs.



OptiNose


Related Nasal Drug Delivery Current Events and Nasal Drug Delivery News Articles


OptiNose's novel intranasal sumatriptan product highly effective in treating migraines
OptiNose, a leader in nasal drug delivery systems, is pleased to announce the publication in Cephalalgia of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the treatment of migraine.

New data on highly effective treatment for chronic rhinosinusitis with nasal polyps
OptiNose is pleased to announce the publication of results from its Phase II clinical study investigating the efficacy and tolerability of its novel, intranasal drug/device product for the topical treatment of chronic rhinosinusitis with nasal polyps in Rhinology, the official journal of the International and European Rhinologic Societies.

OptiNose presents new data on highly effective treatment for chronic rhinosinusitis
OptiNose today announced important new results from a Phase II trial of its novel nasal drug delivery device with fluticasone for the treatment of chronic rhinosinusitis.
More Nasal Drug Delivery Current Events and Nasal Drug Delivery News Articles

Drug Delivery Systems, Third Edition (Pharmacology and Toxicology: Basic and Clinical Aspects)

Drug Delivery Systems, Third Edition (Pharmacology and Toxicology: Basic and Clinical Aspects)
by Vasant V. Ranade (Author), John B. Cannon (Author)


Drug delivery technologies represent a vast and vital area of research and development in pharmaceutics. The demand for innovative drug delivery systems continues to grow, and this growth drives a variety of new developments. Building on the foundation provided by the second edition, Drug Delivery Systems, Third Edition covers the latest in research, development, and regulations in industry and academia. The third edition of this popular book provides a comprehensive review of the latest research and development on drug delivery systems (including liposomal, transmucosal, transdermal, oral, polymeric, and monoclonal antibody directed delivery); it also contains a new chapter on nanoscience and technology for drug delivery along with cutting-edge business intelligence and strategies....

Protein Formulation and Delivery, Second Edition (Drugs and the Pharmaceutical Sciences)

Protein Formulation and Delivery, Second Edition (Drugs and the Pharmaceutical Sciences)
by Eugene J. McNally (Editor), Jayne E. Hastedt (Editor)


This title is intended to assist pharmaceutical scientists in the development of stable protein formulations during the early stages of the product development process, providing a comprehensive review of mechanisms and causes of protein instability in formulation development, coverage of accelerated stability testing methods and relevant analytical methods, and an overview of the drug substance manufacturing process. Preformulation and the development of traditional solutions and lyophilized formulations frequently used for intravenous delivery and non-traditional formulations are also addressed. Because many developments in the field have emerged since the publication of the First Edition, this Second Edition addresses important new patient-friendly developments in the field, such as...

Nasal drug delivery system: Microemulsion as a carrier for intranasal drug delivery system

Nasal drug delivery system: Microemulsion as a carrier for intranasal drug delivery system
by Kumkum Sarangdevot (Author), Bhawani Singh Sonigara (Author), Khem Chand Gupta (Author)


The novel carriers have been exploited through almost all the routes of administration. Many newer carriers are evolving with the advent of technology and the demand of targeted delivery like microemulsions. Microemulsions are clear, stable, isotropic mixtures of oil, water and surfactant. These systems are currently of interest because of their considerable potential to act as drug delivery vehicles by incorporating a wide range of drug molecules. In addition to oral and intravenous delivery, they are amenable for sustained and targeted delivery through nasal, pulmonary, vaginal and topical routes. Intranasal drug delivery system is a promising alternative route of administration for poor bioavailability drugs and it has advantages in term of increase patient acceptibility and...

Drug Permeation Enhancement: Theory and Applications (Drugs and the Pharmaceutical Sciences)

Drug Permeation Enhancement: Theory and Applications (Drugs and the Pharmaceutical Sciences)
by Dean S. Hsieh (Editor)


Providing a comprehensive review of drug permeation enhancement, this reference covers the fundamental aspects of physical and chemical enhancement for the transport of both peptides and nonpeptides through the skin, mucosae, and cornea.;Expanding the frontiers of drug delivery research, drug permeation enhancement details the barrier properties of skin; examines skin penetration enhancers; investigates the transdermal delivery of proteins and peptides by iontophoresis; describes electrically mediated transdermal drug delivery; analyzes obstacles to the transmucosal delivery of peptides and proteins; and discusses ocular peptide absorption mechanisms.;Written by 35 internation authorities working in academia, government, and industry, Drug Permeation Enhancement is for pharmaceutical...

Nasal Drug Delivery: Development and Evaluation of Nasal Formulation

Nasal Drug Delivery: Development and Evaluation of Nasal Formulation
by Basavaraj Nanjwade (Author), Kemy A. Parikh (Author)


Microsphere carrier systems made from the biodegradable polymers have attracted considerable attention for several years in sustained drug delivery. However, the short residence time at the site of absorption could be overcome by coupling bioadhesion characteristics to microspheres and developing bioadhesive microspheres with the help of bioadhesive polymers. Neostigmine Bromide – a cholinesterase inhibitor is widely used for the treatment of Myasthenia Gravis. It is presently marketed in conventional dosage form as a tablet in usual strength of 15-30 mg for peroral route. Extent of absorption of drug through oral route is only 1-2% of 30 mg of administered dose. Hence there is need of novel nasal drug delivery system for the treatment of Myasthenia Gravis. To overcome inherent...

Nasal Systematic Drug Delivery (Drugs and the Pharmaceutical Sciences)

Nasal Systematic Drug Delivery (Drugs and the Pharmaceutical Sciences)
by Yie Chien (Author)




Drug Delivery to the Oral Cavity: Molecules to Market (Drugs and the Pharmaceutical Sciences)

Drug Delivery to the Oral Cavity: Molecules to Market (Drugs and the Pharmaceutical Sciences)
by Tapash K. Ghosh (Editor), William R. Pfister (Editor)


With contributions from recognized authorities in industry, academia, and government, this reference presents the state-of-the-art in the testing, formulation, and clinical evaluation of intraoral drug delivery products-summarizing intraoral dosage forms in various stages of research, as well as products currently on the market.

Leachables and Extractables Handbook: Safety Evaluation, Qualification, and Best Practices Applied to Inhalation Drug Products

Leachables and Extractables Handbook: Safety Evaluation, Qualification, and Best Practices Applied to Inhalation Drug Products
by Douglas J. Ball (Editor), Daniel L. Norwood (Editor), Cheryl L. M. Stults (Editor), Lee M. Nagao (Editor)


A practical and science-based approach for addressing toxicological concerns related to leachables and extractables associated with inhalation drug productsPackaging and device components of Orally Inhaled and Nasal Drug Products (OINDP)—such as metered dose inhalers, dry powder inhalers, and nasal sprays—pose potential safety risks from leachables and extractables, chemicals that can be released or migrate from these components into the drug product. Addressing the concepts, background, historical use, and development of safety thresholds and their utility for qualifying leachables and extractables in OINDP, the Leachables and Extractables Handbook takes a practical approach to familiarize readers with the recent recommendations for safety and risk assessment established through a...

Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines

Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines
by Lene Jorgensen (Editor), Hanne Morck Nielson (Editor)


Advances in biotechnology have provided scientists with an increasing number of biopharmaceuticals such as novel peptide and protein drugs as well as nucleic acid based drugs for gene therapy. However, successful delivery of these biopharmaceuticals is a major challenge because their molecular properties lead to poor physical and chemical stability in the body and limited membrane permeability. Therefore researchers are developing a range of new delivery technologies and materials to enable these new drugs to be delivered intact to their target sites.Delivery Technologies for Biopharmaceuticals describes strategies to overcome the main barriers for successful delivery of therapeutic peptides, proteins, and nucleic acid-based drugs or vaccines related to the site of administration and the...

Nasal drug delivery system (Paperback) - Common

Nasal drug delivery system (Paperback) - Common
by By (author) Sonigara Bhawani Singh, By (author) Gupta Khem Chand By (author) Sarangdevot Kumkum (Author)


The novel carriers have been exploited through almost all the routes of administration. Many newer carriers are evolving with the advent of technology and the demand of targeted delivery like microemulsions. Microemulsions are clear, stable, isotropic mixtures of oil, water and surfactant. These systems are currently of interest because of their considerable potential to act as drug delivery vehic...

© 2014 BrightSurf.com